In healthy cells, Bmf associates with the dynein light chain 2 component of the myosin V motors and is sequestered by the cell’s actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program. Bmf is constitutively expressed in many tissues.
|Product type||Primary antibodies|
|Immunogen||Peptide corresponding to aa 171-184 (C-terminal part )of human Bmf (accession no. NP_277038).|
|Activity cross reaction||Reacts with the C-terminus part of human Bmf.|
|Storage instructions||Stable for at least one year at -20°C. Avoid multiple freeze-thaw cycles.|
|Applications||IF, IHC, WB|
|Working dilutions||Optimal dilution should be determined by the end user.
The following are guidelines only:
WB (2.5 - 5 µg/ml)
IF (10 µg/ml)
Write Your Own Review